Study guide
6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies
Nursing and Midwifery Council of Ghana Licensing Examinations Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: N&MC Ghana Regulation, Licensing Pathway & Examination Format
1.1 Health Professions Regulatory Bodies Act, 2013 (Act 857) & the N&MC Mandate 1.2 Cadres, Indexing, Eligibility, Examination Windows & Fees 1.3 Registration, PIN vs. AIN, Rotation, Licence Renewal & Foreign-Trained Pathway 1.4 Examination Format: Computer-Based Papers, Practical Component, Results & Re-sits
2 Chapter 2: Professional Ethics, Law, Leadership & Patient Rights
2.1 N&MC Ghana Code of Conduct, Ethical Principles & Professional Boundaries 2.2 Ghana Health Service Patients' Charter, Informed Consent & Confidentiality 2.3 Clinical Documentation, Incident Reporting, Negligence & Legal Liability 2.4 Nursing Leadership, Ward Management, Handover & Team Communication
3 Chapter 3: Infection Prevention, Control & Healthcare Safety
3.1 Standard & Transmission-Based Precautions, Hand Hygiene & PPE 3.2 Sterilization, Decontamination & Healthcare Waste Management in Ghana 3.3 Injection Safety, Sharps Injury Prevention & Occupational Post-Exposure Prophylaxis
4 Chapter 4: Clinical Nursing Foundations, Nursing Process & Practical Skills
4.1 Vital Signs Assessment, Clinical Deterioration & Early Warning Scoring 4.2 Medication Administration, Dosages, High-Alert Drugs & Pharmacovigilance 4.3 Enteral & Parenteral Nutrition, Fluid and Electrolyte Balance & Acid-Base Disorders 4.4 Pain Assessment, Analgesic Ladder & Palliative Care in Ghana 4.5 Nursing Process, Care Plans, Care Study & the Practical Examination
5 Chapter 5: Respiratory, Cardiovascular & Neurological Nursing
5.1 Airway, Breathing & Oxygen Therapy: Asthma, COPD & Pneumonia 5.2 Acute Coronary Syndromes, Heart Failure & Shock Classifications 5.3 Hypertension Management, Hypertensive Emergencies & Stroke Care 5.4 Neurological Nursing: Unconscious Patient, Head Injury, Raised ICP & Epilepsy
6 Chapter 6: Endocrine, Renal, Gastrointestinal & Liver Disorders
6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies 6.2 Acute Kidney Injury, Chronic Kidney Disease & Fluid Overload 6.3 Acute Abdomen, Peptic Ulcer Disease & Gastrointestinal Bleeding 6.4 Liver Disease (Hepatitis B, Cirrhosis, Hepatic Encephalopathy) & Thyroid Disorders
7 Chapter 7: Endemic Tropical Infections & Communicable Diseases
7.1 Malaria Management: Diagnostics, Uncomplicated & Severe Malaria Protocols 7.2 Tuberculosis Diagnosis, DOTS Protocol & Infection Control 7.3 HIV/AIDS Management, Antiretroviral Therapy (ART) & Opportunistic Infections 7.4 Enteric Infections: Cholera, Typhoid Fever & Diarrhoea Outbreak Response
8 Chapter 8: Hematology & Common Non-Communicable Conditions
8.1 Sickle Cell Disease: Vaso-Occlusive Crises, Anemia & Organ Protection 8.2 Blood Transfusion Practice, Crossmatching & Transfusion Reactions 8.3 Venous Thromboembolism, Anticoagulation & Pressure Injury Prevention
9 Chapter 9: Perioperative, Urological & Gynaecological Surgical Nursing
9.1 Preoperative Evaluation, Patient Preparation & Informed Consent 9.2 Intraoperative Care, Surgical Asepsis & WHO Surgical Safety Checklist 9.3 Postoperative Complications, Wound Healing & Dressing Techniques 9.4 Anesthesia Overview, Recovery Room (PACU) Care & Pain Management 9.5 Urological Surgical Nursing: Retention, BPH, Prostatectomy, Calculi & Catheter Care 9.6 Gynaecological Nursing: Ectopic Pregnancy, Abortion Care, Fibroids, PID & Cancer Screening
10 Chapter 10: Trauma, Burns & Acute Emergency Management
10.1 ABCDE Primary/Secondary Survey & Disaster Triage (START) 10.2 Major Burns: Rule of Nines, Parkland Fluid Resuscitation & Wound Care 10.3 Fractures, Immobilization, Compartment Syndrome & Spinal Precautions 10.4 Environmental Emergencies: Snakebites, Poisoning & Tetanus Prophylaxis
11 Chapter 11: Maternal Health, Obstetric & Postnatal Nursing
11.1 Antenatal Care (ANC/FANC), Risk Assessment & Health Promotion 11.2 Normal Labor, Stages & Partograph Monitoring 11.3 Obstetric Complications: Postpartum Hemorrhage (PPH) & Active Third Stage (AMTSL) 11.4 Hypertensive Disorders of Pregnancy: Preeclampsia, Eclampsia & MgSO4 11.5 Postnatal Care, Breastfeeding Support & Family Planning
12 Chapter 12: Neonatal & Pediatric Nursing Care
12.1 Immediate Newborn Care, APGAR Scoring & Neonatal Resuscitation 12.2 Integrated Management of Neonatal & Childhood Illness (IMNCI) 12.3 Ghana Expanded Programme on Immunization (EPI) & Pediatric Malnutrition
13 Chapter 13: Community Health Nursing & Primary Healthcare in Ghana
13.1 Community-Based Health Planning and Services (CHPS) Model 13.2 Disease Surveillance, Epidemic Preparedness & Community Health Education 13.3 Environmental Sanitation, Water Safety & School Health Services
14 Chapter 14: Mental Health Nursing & Psychiatric Care
14.1 Mental Health Act, 2012 (Act 846): Authority, Admission Routes & Rights 14.2 Common Psychiatric Disorders: Depression, Bipolar, Schizophrenia & Psychosis 14.3 Psychiatric Emergencies: Suicide Risk Assessment & De-escalation
6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies
Key Takeaways Explain This Topic AI
Diabetes mellitus is diagnosed through standard plasma criteria: fasting blood glucose >= 7.0 mmol/L, 2-hour 75g OGTT >= 11.1 mmol/L, random blood glucose >= 11.1 mmol/L with symptoms, or HbA1c >= 6.5%.
Metformin must be temporarily withheld at the time of and for 48 hours following iodinated intravenous contrast procedures to prevent contrast-induced acute kidney injury and fatal lactic acidosis.
Regular (soluble/Actrapid) insulin is the only insulin preparation approved for intravenous administration in acute glycemic emergencies such as DKA and HHS.
In acute hypoglycemia (< 4.0 mmol/L), conscious patients are managed via the 'Rule of 15', while unconscious patients require immediate IV 50% dextrose (20-50 mL) or IM glucagon (1 mg).
Emergency management of DKA and HHS requires aggressive isotonic fluid resuscitation, with 5% dextrose added when blood glucose drops below 14.0 mmol/L to prevent rapid osmolar shifts and cerebral edema.
Last updated: September 2026
6.1 Diabetes Mellitus, DKA, HHS & Glycemic Emergencies
Quick Answer: Diabetes mellitus is a chronic metabolic disorder of carbohydrate, protein, and fat metabolism characterized by persistent hyperglycemia resulting from insulin deficiency, insulin resistance, or both. In Ghana, clinical practice adheres to World Health Organization (WHO) diagnostic thresholds: fasting blood glucose ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L , random blood glucose ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L with symptoms, or HbA1c ≥ 6.5 % \text{HbA1c} \ge 6.5\% HbA1c ≥ 6.5% . Acute glycemic emergencies include severe hypoglycemia ( < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L ), Diabetic Ketoacidosis (DKA, characterized by metabolic acidosis, ketonemia, and Kussmaul respirations), and Hyperosmolar Hyperglycemic State (HHS, marked by extreme hyperglycemia > 33.3 mmol/L > 33.3\text{ mmol/L} > 33.3 mmol/L and severe hyperosmolality without profound ketosis). Immediate nursing priorities involve aggressive fluid replacement, regular insulin infusion, and vigilant electrolyte monitoring.
Pathophysiology: Type 1 vs. Type 2 Diabetes Mellitus
Diabetes mellitus comprises distinct metabolic etiologies unified by hyperglycemia. A precise understanding of their distinct pathophysiologies is critical for clinical decision-making and licensing examinations.
Type 1 Diabetes Mellitus (T1DM)
Etiology and Mechanism: T1DM is characterized by immune-mediated destruction of pancreatic beta cells within the islets of Langerhans, typically triggered by environmental factors in genetically susceptible individuals (associated with HLA-DR3 and HLA-DR4). This culminates in absolute insulin deficiency .
Metabolic Consequence: Without insulin, target cells cannot take up glucose, triggering intracellular starvation. The counter-regulatory hormones (glucagon, cortisol, epinephrine, growth hormone) surge, stimulating accelerated glycogenolysis, gluconeogenesis, and profound lipolysis. The breakdown of adipose tissue releases free fatty acids, which the liver converts via beta-oxidation into acetoacetate and beta-hydroxybutyrate, causing ketoacidosis.
Epidemiological Pattern: Typically manifests in children, adolescents, and young adults with acute onset of severe symptoms: polyuria, polydipsia, polyphagia, and rapid weight loss.
Type 2 Diabetes Mellitus (T2DM)
Etiology and Mechanism: T2DM arises from a dual defect: peripheral insulin resistance (decreased tissue sensitivity to insulin in skeletal muscle, adipose tissue, and liver) paired with a progressive secretory defect of pancreatic beta cells.
Metabolic Consequence: Because some endogenous insulin secretion persists, lipolysis is sufficiently restrained to prevent massive ketogenesis in ordinary circumstances. However, insulin resistance leads to unsuppressed hepatic glucose production and impaired peripheral uptake. Compensatory hyperinsulinemia eventually gives way to beta-cell exhaustion and progressive hyperglycemia.
Epidemiological Pattern: Represents approximately 90–95% of diabetes cases worldwide and in Ghana. Most common in adults over 30 years old, strongly associated with central obesity, physical inactivity, urban dietary transitions, and positive family history.
Feature Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus
Primary Pathology Autoimmune destruction of pancreatic beta cells Peripheral insulin resistance + beta-cell secretory failure
- Endogenous Insulin Absent or negligible Subnormal, normal, or elevated initially; declines over time
- Body Habitus Lean, wasted, or normal weight Frequently overweight or centrally obese
- Onset of Symptoms Acute, rapid (days to weeks) Insidious, gradual (months to years; often asymptomatic)
Ketosis Prone Highly prone; frequently presents in DKA Resistant; rarely develops ketosis except under severe sepsis
Primary Treatment Exogenous insulin therapy is mandatory for survival Lifestyle modification, oral antidiabetics, non-insulin injectables, insulin
Diagnostic Criteria and Clinical Thresholds
According to Ghana National Standard Treatment Guidelines and WHO/International Diabetes Federation (IDF) standards, diabetes mellitus is confirmed using standardized venous plasma glucose thresholds in SI units ( mmol/L \text{mmol/L} mmol/L ):
Fasting Plasma Glucose (FPG): ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L ( 126 mg/dL 126\text{ mg/dL} 126 mg/dL ) following an overnight fast of at least 8 to 12 hours.
Random Plasma Glucose (RPG): ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L ( 200 mg/dL 200\text{ mg/dL} 200 mg/dL ) in a patient presenting with classic symptoms of hyperglycemia (polyuria, polydipsia, polyphagia, unexplained weight loss).
Two-Hour Oral Glucose Tolerance Test (OGTT): ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L ( 200 mg/dL 200\text{ mg/dL} 200 mg/dL ) two hours after an oral ingestion of 75 g 75\text{ g} 75 g anhydrous glucose dissolved in water.
Glycated Hemoglobin (HbA1c): ≥ 6.5 % \ge 6.5\% ≥ 6.5% ( 48 mmol/mol 48\text{ mmol/mol} 48 mmol/mol ) utilizing an assay standardized to the National Glycohemoglobin Standardization Program (NGSP).
Important
Diagnostic Confirmation Rule: In the absence of unequivocal symptomatic hyperglycemia (classic triad: polyuria, polydipsia, unexplained weight loss), a diagnosis must never be made on a single abnormal test result. The clinician must repeat the test on a separate day using a new blood sample.
Oral Antidiabetic Pharmacotherapy
Oral antidiabetic agents form the backbone of pharmacological management in Type 2 Diabetes Mellitus when lifestyle modifications alone fail to achieve glycemic targets.
1. Biguanides: Metformin
Mechanism of Action: Decreases hepatic gluconeogenesis, reduces intestinal absorption of glucose, and enhances peripheral insulin sensitivity in skeletal muscle.
Key Benefits: Does not stimulate insulin secretion (zero intrinsic risk of hypoglycemia when used as monotherapy), weight-neutral or promotes modest weight loss, cardiovascular benefits.
Major Adverse Effect & Risk: Lactic acidosis (rare but life-threatening). Common GI side effects include abdominal bloating, flatulence, metallic taste, and diarrhea.
Renal Cautions: Metformin is excreted unchanged by the kidneys. It is contraindicated if estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m 2 30\text{ mL/min/1.73 m}^2 30 mL/min/1.73 m 2 and should not be initiated if eGFR is 30 – 45 mL/min/1.73 m 2 30\text{--}45\text{ mL/min/1.73 m}^2 30 – 45 mL/min/1.73 m 2 .
Radiological Contrast Protocol: Metformin must be discontinued at the time of or prior to procedures requiring iodinated intravenous radiocontrast media and withheld for 48 hours post-procedure . It may only be resumed after renal function tests have been repeated and verified as stable, preventing contrast-induced acute tubular necrosis and subsequent fatal metformin accumulation.
2. Sulfonylureas: Glibenclamide & Glimepiride
Mechanism of Action: Act directly as insulin secretagogues by binding to ATP-sensitive potassium channels on pancreatic beta-cell membranes, inducing depolarization, calcium influx, and exocytosis of preformed insulin granules independent of prevailing blood glucose levels.
Major Adverse Effect: Severe, prolonged hypoglycemia and weight gain. Glibenclamide has active metabolites that accumulate in renal impairment; therefore, shorter-acting sulfonylureas (e.g., gliclazide) or lower-dose glimepiride are preferred in elderly individuals or patients with mild-to-moderate renal decline.
Patient Education: Patients must be instructed to eat meals immediately after taking their medication and always carry fast-acting carbohydrates.
Insulin Formulations and Pharmacokinetics
Insulin replacement therapy is indispensable in Type 1 Diabetes Mellitus, advanced Type 2 Diabetes, gestational diabetes, and during acute hospitalizations or surgical interventions.
Insulin Category Generic Formulation (Examples) Appearance Onset of Action Peak Action Window Effective Duration
- Rapid-Acting Insulin Lispro, Insulin Aspart Clear 10–15 minutes 1–2 hours 3–5 hours
- Short-Acting Regular / Soluble Insulin (Actrapid) Clear 30–60 minutes 2–4 hours 6–8 hours
- Intermediate-Acting NPH / Isophane (Insulatard) Cloudy 1–2 hours 4–12 hours 14–24 hours
- Long-Acting Insulin Glargine, Insulin Detemir Clear 1–2 hours Peakless (flat plateau) 20–24 hours
Caution
Critical Route Restriction: Regular (soluble/Actrapid) insulin is the ONLY insulin formulation that can be administered intravenously (IV). Intermediate (NPH) and long-acting (glargine/detemir) insulins are strictly formulated for subcutaneous use; intravenous administration of cloudy NPH or long-acting analogs is lethal.
Injection Technique and Preventing Lipodystrophy
Needle Angle and Depth: Subcutaneous injection should be administered at a 90 ∘ 90^\circ 9 0 ∘ angle into a pinched skin fold to ensure deposition into the subcutaneous tissue rather than underlying skeletal muscle. In emaciated or very lean patients, a 45 ∘ 45^\circ 4 5 ∘ angle is employed.
Systematic Site Rotation: Injection sites encompass the abdomen (fastest, most predictable absorption rate), anterolateral thighs, upper outer arms, and upper buttocks. Patients must systematically rotate sites within the same anatomical region (e.g., leaving a 2.5 cm 2.5\text{ cm} 2.5 cm or 1-inch space between consecutive injections) for one to two weeks before moving to another region.
Preventing Lipohypertrophy: Repeated injections into the same unrotated skin area produce fibrous, fatty subcutaneous nodules ( lipohypertrophy ). Injecting insulin into lipohypertrophic tissue results in delayed, erratic, and unpredictable drug absorption, causing alternating unexplained hyperglycemia and refractory hypoglycemia.
Acute Hypoglycemia Protocol ( < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L )
Hypoglycemia is defined as a plasma glucose level < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L ( 70 mg/dL 70\text{ mg/dL} 70 mg/dL ). It represents a medical emergency that demands instantaneous intervention. CLINICAL HYPOGLYCEMIA
- (< 4.0 mmol/L)
- |
- +-------------------+-------------------+
- | |
- [CONSCIOUS PATIENT] [UNCONSCIOUS PATIENT]
- | |
- "Rule of 15": Protect Airway (Recovery Position)
- 15 g Simple Carbohydrates |
- (3-4 sugar cubes / 150 mL juice) IV Access Present? ----+
- | | |
- Wait 15 Mins -> Recheck YES NO
- | | |
- +--------------+--------------+ 50% Dextrose Glucagon 1 mg
- | | (20-50 mL IV) (IM / SC)
- < 4.0 mmol/L >= 4.0 mmol/L
- | |
- Repeat 15 g Carbs Complex Carb Snack / Meal
- Clinical Manifestations: Adrenergic vs. Neuroglycopenic
Adrenergic / Autonomic Signs (Sympathetic Nervous System Surge): Manifest first as counter-regulatory catecholamines are released to raise blood glucose. Features include tremors, diaphoresis (cold sweats), tachycardia, palpitations, hunger, pallor, anxiety, and restlessness.
Neuroglycopenic Signs (CNS Glucose Deprivation): Manifest when the brain is starved of glucose. Features include confusion, irritability, slurred speech, visual disturbances, ataxia, bizarre behavior, drowsiness, seizures, and irreversible coma.
Emergency Management: Conscious vs. Unconscious Protocols
Conscious Patient Protocol ("The Rule of 15"):
Immediately administer 15 g 15\text{ g} 15 g of rapid-acting simple carbohydrate orally: 3–4 sugar cubes, 3 teaspoons ( 15 mL 15\text{ mL} 15 mL ) of table sugar dissolved in water, or 150 mL 150\text{ mL} 150 mL of regular fruit juice/soda. Avoid milk, chocolate, or pastries (fat delays gastric emptying and glucose absorption).
Rest for 15 minutes , then recheck capillary blood glucose.
If blood glucose remains < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L , administer another 15 g 15\text{ g} 15 g of simple carbohydrate and re-evaluate in 15 minutes.
Once blood glucose is ≥ 4.0 mmol/L \ge 4.0\text{ mmol/L} ≥ 4.0 mmol/L , provide a complex carbohydrate and protein snack (e.g., bread with peanut butter, a cup of porridge, or an advance of the scheduled meal) to sustain blood glucose and prevent secondary rebound hypoglycemia.
Unconscious Patient Protocol (Impaired Swallowing / Coma):
Do not administer anything orally due to extreme aspiration risk.
Maintain patent airway and position the patient in the lateral recovery position.
Establish IV access: Administer 20 – 50 mL 20\text{--}50\text{ mL} 20 – 50 mL of 50 % 50\% 50% Dextrose in Water (D50W) as a slow intravenous push over 3 to 5 minutes through a freely patent large-bore cannula (extravasation causes chemical tissue necrosis).
If IV access is unavailable: Administer 1 mg 1\text{ mg} 1 mg Glucagon intramuscularly (IM) or subcutaneously. Turn the patient on their side because glucagon frequently induces nausea and vomiting upon consciousness restoration.
Hyperglycemic Crises: DKA vs. HHS
Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) are severe, life-threatening decompensations requiring urgent intensive nursing interventions.
- Clinical Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
- Usual Patient Group Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus (often elderly, debilitated)
Precipitating Factors Omission of insulin, infection (malaria, pneumonia, UTI), stress, trauma Sepsis, severe dehydration, stroke, MI, glucocorticoid therapy
Onset Speed Acute, rapid ( < 24 hours < 24\text{ hours} < 24 hours ) Insidious, slow (days to several weeks)
Blood Glucose Typically 14.0 – 30.0 mmol/L 14.0\text{--}30.0\text{ mmol/L} 14.0 – 30.0 mmol/L ( 250 – 550 mg/dL 250\text{--}550\text{ mg/dL} 250 – 550 mg/dL ) Profound: ≥ 33.3 mmol/L \ge 33.3\text{ mmol/L} ≥ 33.3 mmol/L ( > 600 mg/dL > 600\text{ mg/dL} > 600 mg/dL )
Arterial Blood pH Acidotic: pH < 7.30 \text{pH} < 7.30 pH < 7.30 (severe: < 7.00 < 7.00 < 7.00 ) Normal or mildly reduced: pH > 7.30 \text{pH} > 7.30 pH > 7.30
Serum Bicarbonate Low: < 15 mmol/L < 15\text{ mmol/L} < 15 mmol/L (severe: < 10 mmol/L < 10\text{ mmol/L} < 10 mmol/L ) Normal to slightly reduced: ≥ 18 mmol/L \ge 18\text{ mmol/L} ≥ 18 mmol/L
Ketones (Serum/Urine) Positive: moderate to high Absent, trace, or mildly positive
Effective Osmolality Variable, typically < 320 mOsm/kg < 320\text{ mOsm/kg} < 320 mOsm/kg Markedly elevated: > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg
Respiratory Pattern Kussmaul respirations (rapid, deep, sighing) with fruity/acetone breath odor Normal respirations; no acetone breath
Neurological State Alert, lethargic, or drowsy Severe alteration: profound stupor, focal deficits, coma
Fluid Deficit Significant ( 3 – 6 L 3\text{--}6\text{ L} 3 – 6 L or 100 mL/kg 100\text{ mL/kg} 100 mL/kg ) Massive ( 8 – 10 L 8\text{--}10\text{ L} 8 – 10 L or 100 – 200 mL/kg 100\text{--}200\text{ mL/kg} 100 – 200 mL/kg )
Emergency Nursing Management Protocol for DKA and HHS
The management of DKA and HHS follows structured clinical resuscitation protocols prioritizing fluid resuscitation, regular insulin delivery, potassium correction, and electrolyte stabilization.
1. Fluid Resuscitation (Volume Restoration First)
Initial Fluid: Infuse 0.9 % 0.9\% 0.9% Normal Saline ( 1 L/hr 1\text{ L/hr} 1 L/hr initially or 15 – 20 mL/kg/hr 15\text{--}20\text{ mL/kg/hr} 15 – 20 mL/kg/hr ) for the first 1 to 2 hours to expand effective intravascular volume, reverse hypovolemic shock, and restore renal perfusion.
Secondary Fluid: Once hemodynamically stable, adjust IV fluids to 0.45 % 0.45\% 0.45% Normal Saline (if corrected sodium is normal or high) or continue 0.9 % 0.9\% 0.9% Normal Saline (if sodium is low) at 250 – 500 mL/hr 250\text{--}500\text{ mL/hr} 250 – 500 mL/hr .
Preventing Cerebral Edema: When blood glucose drops to 14.0 mmol/L 14.0\text{ mmol/L} 14.0 mmol/L ( 250 mg/dL 250\text{ mg/dL} 250 mg/dL ) in DKA (or 16.7 mmol/L 16.7\text{ mmol/L} 16.7 mmol/L [ 300 mg/dL 300\text{ mg/dL} 300 mg/dL ] in HHS), immediately switch or add 5 % 5\% 5% Dextrose in 0.45 % 0.45\% 0.45% Saline (or 5 % 5\% 5% Dextrose in Water). This maintains blood glucose between 11.0 – 14.0 mmol/L 11.0\text{--}14.0\text{ mmol/L} 11.0 – 14.0 mmol/L while insulin infusion continues to clear ketoacids, preventing sudden osmotic shifts that trigger fatal cerebral edema .
2. Continuous Intravenous Insulin Infusion
Administer Regular (soluble) insulin via continuous IV infusion at a fixed rate of 0.1 units/kg/hr 0.1\text{ units/kg/hr} 0.1 units/kg/hr .
Target a gradual reduction in blood glucose of 3.0 – 4.0 mmol/L/hr 3.0\text{--}4.0\text{ mmol/L/hr} 3.0 – 4.0 mmol/L/hr ( 50 – 75 mg/dL/hr 50\text{--}75\text{ mg/dL/hr} 50 – 75 mg/dL/hr ) . Precipitous falls in plasma osmolality must be avoided.
3. Potassium Replacement Protocol
Serum Potassium Check: Insulin drives potassium into intracellular compartments, precipitating lethal cardiac dysrhythmias.
Rule 1: If serum potassium is < 3.3 mmol/L < 3.3\text{ mmol/L} < 3.3 mmol/L , hold insulin and infuse IV potassium chloride ( 20 – 40 mEq/hr 20\text{--}40\text{ mEq/hr} 20 – 40 mEq/hr ) until K + > 3.3 mmol/L \text{K}^+ > 3.3\text{ mmol/L} K + > 3.3 mmol/L .
Rule 2: If serum potassium is between 3.3 – 5.2 mmol/L 3.3\text{--}5.2\text{ mmol/L} 3.3 – 5.2 mmol/L , add 20 – 30 mEq 20\text{--}30\text{ mEq} 20 – 30 mEq of potassium chloride to each liter of IV replacement fluid to keep serum potassium between 4.0 – 5.0 mmol/L 4.0\text{--}5.0\text{ mmol/L} 4.0 – 5.0 mmol/L .
Rule 3: If potassium is > 5.2 mmol/L > 5.2\text{ mmol/L} > 5.2 mmol/L , do not administer potassium, but monitor levels every 2 hours alongside continuous cardiac telemetry.
Tip
Nursing Monitoring Standards: Insert an indwelling urinary catheter to document strict hourly urine output (minimum target ≥ 0.5 mL/kg/hr \ge 0.5\text{ mL/kg/hr} ≥ 0.5 mL/kg/hr or 30 – 50 mL/hr 30\text{--}50\text{ mL/hr} 30 – 50 mL/hr ). Check hourly capillary blood glucose, review venous electrolytes and venous blood gases every 2 to 4 hours, and conduct Glasgow Coma Scale (GCS) checks to detect early signs of rising intracranial pressure.